Labcorp Holdings Inc. EVP Resigns; Leadership Shift in Lab Services

What Happened Labcorp Holdings Inc. filed an 8-K on August 14, 2026 reporting that Megan D. Bailey notified the company on August 11, 2026 that she will resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Effective September 1, 2026, Brian J. Caveney, M.D. — currently Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer — will become Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, overseeing both the Early Development Research Laboratories and Central Laboratories businesses.

Key Details

• Filing date: Form 8-K filed August 14, 2026 (notice given August 11, 2026).
• Megan D. Bailey resignation effective: September 4, 2026.
• Brian J. Caveney role change effective: September 1, 2026; will have responsibility for Early Development Research Laboratories and Central Laboratories.
• Caveney retains title of Chief Medical and Scientific Officer while assuming expanded operational oversight.

Why It Matters This is an executive leadership change affecting Labcorp’s laboratory service lines (Central Laboratories and Early Development Research Laboratories). For investors, the filing signals a planned, near-term transition in operational leadership rather than an unexpected departure; the company has named an internal executive (Dr. Caveney) to lead the combined units, which may support continuity in scientific and operational oversight. The 8-K does not include compensation changes or performance guidance tied to the transition.